PRAX Q3 2024 Earnings — Praxis Precision Medicines, Inc. Revenue & Financial Results | Market Cap Arena

PRAXPraxis Precision Medicines, Inc.

$7B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$302,000-35.5% YoY

Gross Profit

-$42M-13767.9% margin

Operating Income

-$57M-18819.5% margin

Net Income

-$52M-17188.7% margin

EPS (Diluted)

$-2.75

QoQ Revenue Growth

-15.4%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$28M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$416M

Total Liabilities

$34M

Stockholders' Equity

$383M

Cash & Equivalents

$169M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$302,000	$468,000	-35.5%
Gross Profit	-$42M	-$17M	-147.6%
Operating Income	-$57M	-$26M	-122.7%
Net Income	-$52M	-$25M	-110.7%